Jupiter Neurosciences (JUNS) vs Redhill Biopharma (RDHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Redhill Biopharma is the larger company by market cap ($4.7 million vs $3.6 million), about 1.3 times the size. On valuation, Redhill Biopharma trades at a lower forward P/E (17.6x vs 45.8x for Jupiter Neurosciences).
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | JUNS | RDHL |
|---|---|---|
| Share price | $2.75 | $0.5291 |
| Market cap | $3.63M | $4.70M |
| 1-day change | -3.15% | +11.62% |
| Forward P/E | 45.83 | 17.64 |
| EPS (TTM) | $-18.94 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $135.75 | $2.14 |
| 52-week low | $2.25 | $0.4351 |
| Distance from 52-week high | -97.97% | -75.28% |
| Average volume | 982.67K | 1.81M |
| Shares outstanding | 1.32M | 8.89M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
JUNS vs RDHL FAQ
Which is bigger, Jupiter Neurosciences or Redhill Biopharma?
Redhill Biopharma (RDHL) is larger, with a market capitalization of $4.70M compared with $3.63M for Jupiter Neurosciences (JUNS).
Are Jupiter Neurosciences and Redhill Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.